Exploiting inflammation for therapeutic gain in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy associated with <5% 5-year survival, in which standard chemotherapeutics have limited benefit. The disease is associated with significant intra- and peritumoral inflammation and failure of protective immunosurveillance. Indeed, i...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Steele, C W, Jamieson, N B, Evans, T R J, McKay, C J, Sansom, O J, Morton, J P, Carter, C R
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2013
Témata:
Minireview
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3619061/
https://ncbi.nlm.nih.gov/pubmed/23385734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.24
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky